CLOs on the Move

NY Presbyterian Community Health Plan

www.nypchp.org

 
NY Presbyterian Community Health Plan is a New York, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

First Managed Care Option

First MCO is unique in the worker`s compensation industry in that it develops networks of specialists where the employers have the ability to direct care to them. With a rich 36-year company history, First MCO has grown into national experts in driving care for private and public sectors. The company works with insurance companies, self-insurers, third party administrators and insurance funds to provide comprehensive medical management and cost containment services for workers` compensation in New Jersey, Nevada, Missouri, Pennsylvania, Virginia, and Connecticut. The skilled medical team and professional staff at First MCO pride themselves on individualized customer service and convenient managed care solutions to get people back to work.

Eden Spine

Eden Spine is a Lake Mary, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SWIFT COUNTY BENSON HOSP

SWIFT COUNTY BENSON HOSP is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Benson, MN. To find more information about SWIFT COUNTY BENSON HOSP, please visit www.scbh.org

OnPoint Medical Diagnosis

OnPoint Medical Diagnosis is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Minneapolis, MN. To find more information about OnPoint Medical Diagnosis, please visit www.onpointmd.com

Dimension Therapeutics

Dimension Therapeutics, Inc. is a rare disease company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced adeno-associated virus (AAV) delivery technology. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from OTC deficiency and GSDIa; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in hemophilia B, which is expected to enter clinical testing in the second half of 2015. Dimension has preferred access to multiple AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases.